PE20142099A1 - Derivados de sulfonamida - Google Patents
Derivados de sulfonamidaInfo
- Publication number
- PE20142099A1 PE20142099A1 PE2014001348A PE2014001348A PE20142099A1 PE 20142099 A1 PE20142099 A1 PE 20142099A1 PE 2014001348 A PE2014001348 A PE 2014001348A PE 2014001348 A PE2014001348 A PE 2014001348A PE 20142099 A1 PE20142099 A1 PE 20142099A1
- Authority
- PE
- Peru
- Prior art keywords
- het2
- chloro
- thiazol
- phenyl
- refers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C07D263/50—Benzene-sulfonamido oxazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE Z ES HET2, OPCIONALMENTE SUSTITUIDO; Y1, Y2, Y3 E Y4 SON INDEPENDIENTEMENTE ENTRE SI CH, CR1 O N; R1 ES HALO, CIANO, AMINO, ALQUILO C1-C4, ENTRE OTROS; B ES FENILO O HET2; X ESTA AUSENTE O ES -O-, METILENO, ETILENO, ENTRE OTROS; C ES CICLOALQUILO C3-C8, FENILO, HET2, ENTRE OTROS; HET2 ES HETEROCICLICO AROMATICO C5-C6. SON COMPUESTOS PREFERIDOS: 4-[2-(6-AMINOPIRIDIN-3-IL)-4-FLUOROFENOXI]-N-(5-CLORO-1,3-TIAZOL-2-IL)-3-CIANOBENCENOSULFONAMIDA; 5-CLORO-4-(4-CLORO-2-PIPERIDIN-4-ILFENOXI)-2-FLUORO-N-1,3-TIAZOL-4-ILBENCENOSULFONAMIDA; ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UTIL EN EL TRATAMIENTO DEL DOLOR.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14392009P | 2009-01-12 | 2009-01-12 | |
US24572609P | 2009-09-25 | 2009-09-25 | |
US25876009P | 2009-11-06 | 2009-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20142099A1 true PE20142099A1 (es) | 2014-12-13 |
Family
ID=41818828
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001300A PE20120008A1 (es) | 2009-01-12 | 2010-01-06 | Derivados de fenoxi bencenosulfonamida |
PE2014001348A PE20142099A1 (es) | 2009-01-12 | 2010-01-06 | Derivados de sulfonamida |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2011001300A PE20120008A1 (es) | 2009-01-12 | 2010-01-06 | Derivados de fenoxi bencenosulfonamida |
Country Status (42)
Families Citing this family (112)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2009235634B8 (en) * | 2008-04-08 | 2013-05-23 | Grunenthal Gmbh | Substituted sulfonamide derivatives |
PT2385938E (pt) * | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Derivados de sulfonamida |
DE102009058280A1 (de) * | 2009-12-14 | 2011-06-16 | Merck Patent Gmbh | Thiazolderivate |
CA2789606A1 (en) | 2010-02-25 | 2011-09-01 | Pfizer Limited | Peptide analogues as opioid receptor agonists |
CA2804173C (en) * | 2010-07-09 | 2015-01-13 | Pfizer Limited | Sulfonamide nav1.7 inhibitors |
WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
EP2593427B1 (en) | 2010-07-12 | 2014-12-24 | Pfizer Limited | Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain |
WO2012007868A2 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP2593432B1 (en) | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
US9102621B2 (en) | 2010-07-12 | 2015-08-11 | Pfizer Limited | Acyl sulfonamide compounds |
EP2593433B1 (en) | 2010-07-12 | 2014-11-26 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
CN103153955A (zh) | 2010-09-17 | 2013-06-12 | 普渡制药公司 | 吡啶化合物及其用途 |
EA201370161A1 (ru) | 2011-01-18 | 2013-12-30 | Амген Инк. | НОКАУТНЫЕ ПО Na1.7 МЫШИ И ИХ ПРИМЕНЕНИЕ |
WO2012120398A1 (en) | 2011-03-04 | 2012-09-13 | Pfizer Limited | Aryl substituted carboxamide derivatives as trpm8 modulators |
WO2012137089A1 (en) | 2011-04-05 | 2012-10-11 | Pfizer Limited | Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
TW201837023A (zh) * | 2011-07-01 | 2018-10-16 | 美商基利科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
ES2564366T3 (es) | 2011-07-13 | 2016-03-22 | Pfizer Limited | Análogos de encefalina |
PT2750677T (pt) | 2011-08-30 | 2017-07-03 | Chdi Foundation Inc | Inibidores de quinurenina-3-monooxigenase, composições farmacêuticas e métodos de utilização dos mesmos |
JP5363636B2 (ja) * | 2011-10-21 | 2013-12-11 | ファイザー・リミテッド | 新規な塩および医学的使用 |
AU2012328561A1 (en) | 2011-10-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
JP6014154B2 (ja) * | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドXenon Pharmaceuticals Inc. | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
US9481677B2 (en) | 2011-10-31 | 2016-11-01 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
WO2013093688A1 (en) | 2011-12-19 | 2013-06-27 | Pfizer Limited | Sulfonamide derivatives and use thereof as vgsc inhibitors |
EP2800740A1 (en) * | 2012-01-04 | 2014-11-12 | Pfizer Limited | N-aminosulfonyl benzamides |
US8889741B2 (en) * | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
WO2013161929A1 (ja) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | ピリジニルモルホリノン誘導体およびそれらを含有する医薬組成物 |
WO2013161928A1 (ja) * | 2012-04-26 | 2013-10-31 | 塩野義製薬株式会社 | オキサゾロトリアゾール誘導体およびそれらを含有する医薬組成物 |
WO2013177224A1 (en) | 2012-05-22 | 2013-11-28 | Genentech, Inc. | N-substituted benzamides and their use in the treatment of pain |
SG11201408324QA (en) | 2012-06-12 | 2015-01-29 | Abbvie Inc | Pyridinone and pyridazinone derivatives |
WO2014008458A2 (en) | 2012-07-06 | 2014-01-09 | Genentech, Inc. | N-substituted benzamides and methods of use thereof |
EP2912036A1 (en) | 2012-10-04 | 2015-09-02 | Pfizer Limited | Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors |
US20150250785A1 (en) | 2012-10-04 | 2015-09-10 | Pfizer Limited | Tropomyosin-Related Kinase Inhibitors |
JP2015531394A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドPfizer Limited | ピロロ[2,3−d]ピリミジントロポミオシン関連キナーゼ阻害剤 |
US9376429B2 (en) * | 2012-10-15 | 2016-06-28 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
EP2911663B1 (en) | 2012-10-26 | 2020-03-18 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
UA112028C2 (uk) | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
ES2663798T3 (es) | 2013-03-14 | 2018-04-17 | Daiichi Sankyo Company, Limited | Fármaco para enfermedades respiratorias |
BR112015022096A8 (pt) | 2013-03-15 | 2019-11-26 | Chromocell Corp | compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos |
WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
CA2903220C (en) | 2013-03-15 | 2023-01-24 | Qing Xu | Aldehyde compounds and uses thereof for the modulation of hemoglobin |
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
MA38661A1 (fr) | 2013-06-27 | 2017-03-31 | Pfizer | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
SI3043784T1 (sl) | 2013-09-09 | 2019-08-30 | Peloton Therapeutics, Inc. | Aril etri in njihova uporaba |
UA120353C2 (uk) * | 2013-09-10 | 2019-11-25 | Хромоселл Корпорейшн | Модулятори натрієвого каналу для лікування болю і діабету |
EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
PE20161247A1 (es) | 2013-11-27 | 2016-11-30 | Genentech Inc | Benzamidas sustituidas y metodos para usarlas |
EP3083602A1 (en) | 2013-12-20 | 2016-10-26 | Pfizer Limited | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2015159175A1 (en) | 2014-04-15 | 2015-10-22 | Pfizer Inc. | Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety |
EP3140298A1 (en) | 2014-05-07 | 2017-03-15 | Pfizer Inc. | Tropomyosin-related kinase inhibitors |
CA2950393A1 (en) | 2014-05-30 | 2015-12-03 | Pfizer Inc. | Benzenesulfonamides useful as sodium channel inhibitors |
US9802945B2 (en) | 2014-06-12 | 2017-10-31 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the GABAA receptor activity |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
WO2016009296A1 (en) | 2014-07-16 | 2016-01-21 | Pfizer Inc. | N-acylpiperidine ether tropomyosin-related kinase inhibitors |
WO2016009303A1 (en) | 2014-07-17 | 2016-01-21 | Pfizer Inc. | Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors |
KR20170026633A (ko) | 2014-07-17 | 2017-03-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | Hiv-관련 장애의 치료 방법 및 치료용 조성물 |
WO2016020784A1 (en) | 2014-08-05 | 2016-02-11 | Pfizer Inc. | N-acylpyrrolidine ether tropomyosin-related kinase inhibitors |
WO2016034971A1 (en) | 2014-09-04 | 2016-03-10 | Pfizer Limited | Sulfonamides derivatives as urat1 inhibitors |
EP3193610A4 (en) * | 2014-09-09 | 2018-04-04 | Chromocell Corporation | Selective nav1.7 inhibitors for the treatment of diabetes |
WO2016067143A1 (en) | 2014-10-28 | 2016-05-06 | Pfizer Inc. | N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels |
KR102412146B1 (ko) | 2015-02-11 | 2022-06-22 | 주식회사 아이엔테라퓨틱스 | 소디움 채널 차단제 |
US10512626B2 (en) | 2015-03-11 | 2019-12-24 | Peloton Therapeautics, Inc. | Compositions for use in treating glioblastoma |
EP3267792A4 (en) | 2015-03-11 | 2018-09-26 | Peloton Therapeutics, Inc. | Compositions for use in treating pulmonary arterial hypertension |
WO2016144825A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Aromatic compounds and uses thereof |
WO2016144826A1 (en) | 2015-03-11 | 2016-09-15 | Peloton Therapeutics, Inc. | Substituted pyridines and uses thereof |
US10335388B2 (en) | 2015-04-17 | 2019-07-02 | Peloton Therapeutics, Inc. | Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof |
CA2986045A1 (en) | 2015-05-22 | 2016-12-01 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
ES2858551T3 (es) * | 2015-06-16 | 2021-09-30 | Atxa Therapeutics Ltd | Antagonistas del receptor de tromboxano |
JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック, インコーポレイテッド | 治療化合物及びその使用方法 |
PE20181003A1 (es) | 2015-09-28 | 2018-06-26 | Genentech Inc | Compuestos terapeuticos y sus metodos de uso |
CA3002920A1 (en) * | 2015-11-06 | 2017-05-11 | Daiichi Sankyo Company, Limited | Method for removing dimethoxybenzyl group |
CA3003119C (en) * | 2015-11-13 | 2019-10-22 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blocker |
WO2017091592A1 (en) | 2015-11-25 | 2017-06-01 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
SI3386591T1 (sl) | 2015-12-09 | 2020-11-30 | Cadent Therapeutics, Inc. | Heteroaromatski NMDA receptorski modulatorji in njihove uporabe |
EP4219507A3 (en) | 2015-12-09 | 2023-08-16 | Novartis AG | Thienopyrimidinone nmda receptor modulators and uses thereof |
EP3386983A1 (en) | 2015-12-10 | 2018-10-17 | Pfizer Limited | 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain |
TN2018000195A1 (en) | 2015-12-18 | 2019-10-04 | Merck Sharp & Dohme | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
AU2016370677A1 (en) | 2015-12-18 | 2018-06-07 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
WO2017153952A1 (en) * | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
US10442778B2 (en) | 2016-03-22 | 2019-10-15 | Merck Sharp & Dohme Corp. | N1-phenylpropane-1,2-diamine compounds with selective activity in voltage-gated sodium channels |
CN106397425A (zh) * | 2016-03-29 | 2017-02-15 | 广东环境保护工程职业学院 | 一种1,3,4-噻二唑类化合物及其制备方法 |
CN106397426A (zh) * | 2016-03-29 | 2017-02-15 | 广东环境保护工程职业学院 | 一种1,3,4-噻二唑类化合物及其制备方法 |
EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
SG11201809702SA (en) | 2016-05-20 | 2018-12-28 | Xenon Pharmaceuticals Inc | Benzenesulfonamide compounds and their use as therapeutic agents |
WO2017202376A1 (zh) * | 2016-05-26 | 2017-11-30 | 南京明德新药研发股份有限公司 | 磺酰胺衍生物 |
RU2019114964A (ru) * | 2016-10-17 | 2020-11-17 | Дженентек, Инк. | Терапевтические средства и способы их применения |
JP7022751B2 (ja) | 2016-12-09 | 2022-02-18 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ベンゼンスルホンアミド化合物および治療剤としてのそれらの使用 |
AU2017382339B2 (en) | 2016-12-22 | 2024-02-15 | Novartis Ag | NMDA receptor modulators and uses thereof |
EP3601262B1 (en) * | 2017-03-23 | 2022-11-09 | Aurigene Discovery Technologies Limited | Process for the preparation of a sulfonamide structured kinase inhibitor |
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
US11020381B2 (en) | 2017-08-31 | 2021-06-01 | Raqualia Pharma Inc. | Biaryloxy derivatives as TTX-S blockers |
AR114263A1 (es) * | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
TW202003490A (zh) * | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
UA127024C2 (uk) | 2018-06-13 | 2023-03-15 | Ксенон Фармасьютікалз Інк. | Бензолсульфонамідні сполуки та їх застосування як терапевтичних агентів |
GB201810092D0 (en) * | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
DK3830092T3 (en) | 2018-08-03 | 2023-08-07 | Novartis Ag | Heteroaromatic nmda receptor modulators and uses thereof |
KR20210054510A (ko) | 2018-08-31 | 2021-05-13 | 제논 파마슈티칼스 인크. | 헤테로아릴-치환된 술폰아미드 화합물 및 치료제로서의 그의 용도 |
CN112638898B (zh) | 2018-08-31 | 2024-04-09 | 泽农医药公司 | 杂芳基取代的磺酰胺化合物及其作为钠通道抑制剂的用途 |
WO2020117626A1 (en) | 2018-12-05 | 2020-06-11 | Merck Sharp & Dohme Corp. | 4-amino or 4-alkoxy-substituted aryl sulfonamide compounds with selective activity in voltage-gated sodium channels |
CN111285825B (zh) * | 2018-12-10 | 2023-02-17 | 中国科学院上海药物研究所 | 一类苯磺酰胺取代的衍生物,其制法及其用途 |
CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
JP2023530231A (ja) * | 2020-06-03 | 2023-07-14 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 転写増強アソシエートドメイン(tead)阻害剤及びその使用 |
CN114073698B (zh) * | 2020-08-20 | 2023-03-31 | 山西泰睿鑫科技有限公司 | 一种止痛止痒药物组合物及其应用方法 |
CN112625030A (zh) * | 2020-12-25 | 2021-04-09 | 杭州澳赛诺生物科技有限公司 | 一种一锅法合成n-保护3-溴代吡唑的合成方法 |
US11918572B2 (en) * | 2022-01-28 | 2024-03-05 | Rebel Medicine Inc | Pharmaceutical compositions for treating pain |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3905971A (en) | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
DE3531919A1 (de) | 1985-09-07 | 1987-03-19 | Hoechst Ag | Substituierte 2-phenyl-hexahydro-1,2,4-triazin-3,5-dione, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung |
DE3540654A1 (de) | 1985-11-13 | 1987-05-14 | Schering Ag | Phenoxy-substituierte ss-carbolinderivate, ihre herstellung und ihre verwendung als arzneimittel |
US5591761A (en) | 1993-05-20 | 1997-01-07 | Texas Biotechnology Corporation | Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin |
JPH0264538A (ja) | 1988-08-31 | 1990-03-05 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料 |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
DE69206725T2 (de) | 1991-09-10 | 1996-05-02 | Zeneca Ltd | Benzolsulfonamidderivate als 5-Lipoxygenasehemmer |
GB2263635A (en) | 1992-01-28 | 1993-08-04 | Merck & Co Inc | Substitiuted triazoles as neurotensin antagonists |
US5219856A (en) | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
NZ247440A (en) | 1992-05-06 | 1995-04-27 | Squibb & Sons Inc | Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
EP0906310A4 (en) | 1996-06-07 | 1999-09-01 | Merck & Co Inc | OXADIAZOLE-BENZOSULFONAMIDES AS SELECTIVE BETA-3 ADRENERGIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETIS AND OBESITY |
US6548524B2 (en) | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
EP0937723A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
DK1041072T3 (da) | 1999-03-31 | 2003-11-10 | Pfizer Prod Inc | Dioxocyclopentylhydroxamsyrer |
PT1181286E (pt) | 1999-05-28 | 2004-02-27 | Pfizer Prod Inc | Hidroxamidas de acido 3-(arilsulfonilamino)-tetrahidropirano-3-carboxilico |
HN2000000052A (es) | 1999-05-28 | 2001-02-02 | Pfizer Prod Inc | Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos. |
KR20020012639A (ko) | 1999-07-29 | 2002-02-19 | 우에노 도시오 | 술폰아미드 유도체 및 알로디니아 치료제 |
PT1088819E (pt) | 1999-09-30 | 2005-09-30 | Pfizer Prod Inc | Derivados de 6-azauracilo como lignados de receptores da tiroide |
US20020065303A1 (en) | 2000-02-01 | 2002-05-30 | Bing-Yan Zhu | Bivalent phenylene inhibitors of factor Xa |
CN1251671C (zh) | 2000-05-19 | 2006-04-19 | 武田药品工业株式会社 | β分泌酶抑制剂 |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
JP2003081937A (ja) * | 2001-09-07 | 2003-03-19 | Bayer Ag | ベンゼンスルホンアミド誘導体 |
WO2003048159A1 (en) | 2001-12-05 | 2003-06-12 | Astrazeneca Ab | Quinoline derivatives |
US20030158186A1 (en) | 2001-12-21 | 2003-08-21 | Fady Malik | Compositions and methods for treating heart failure |
KR101116627B1 (ko) | 2002-06-27 | 2012-10-09 | 노보 노르디스크 에이/에스 | 치료제로서 아릴 카르보닐 유도체 |
NZ538339A (en) | 2002-08-09 | 2007-01-26 | Astrazeneca Ab | Oxadiazoles as modulators of metabotropic glutamate receptor-5 |
US7169797B2 (en) | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
DK1608374T5 (da) | 2003-03-24 | 2010-01-25 | Axikin Pharmaceuticals Inc | 2-Phenoxy- og 2-phenylsulfanylbenzensulfonamidderivater med CCR3-antagonistisk aktivitet til behandling af astma og andre inflammatoriske eller immunologiske sygdomme |
WO2004103980A1 (en) | 2003-05-21 | 2004-12-02 | Biovitrum Ab | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
EP1653952A4 (en) | 2003-08-06 | 2007-04-04 | Pfizer Prod Inc | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER |
NZ545710A (en) * | 2003-08-08 | 2010-02-26 | Vertex Pharma | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
US7378414B2 (en) | 2003-08-25 | 2008-05-27 | Abbott Laboratories | Anti-infective agents |
US20070082907A1 (en) | 2003-11-25 | 2007-04-12 | Eli Lilly And Company | Peroxisome proliferator activated receptor modulators |
ZA200605247B (en) | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | N-substituted-n-sulfonylaminocyclopropane compounds and pharmaceutical use thereof |
JP4185154B2 (ja) | 2004-04-30 | 2008-11-26 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | 中枢神経系障害治療用の置換モルホリン化合物 |
WO2005116026A1 (en) | 2004-05-24 | 2005-12-08 | F. Hoffmann-La Roche Ag | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide |
WO2006002284A1 (en) | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
RU2416608C2 (ru) | 2004-08-06 | 2011-04-20 | Оцука Фармасьютикал Ко., Лтд. | Ароматическое соединение |
PE20090123A1 (es) | 2004-09-13 | 2009-03-10 | Ono Pharmaceutical Co | Un derivado heterociclico conteniendo nitrogeno y un farmaco conteniendo el mismo como el ingrediente activo |
SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
US20080015223A1 (en) | 2004-12-03 | 2008-01-17 | Arena Pharmaceuticals, Inc. | Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto |
PL2354126T3 (pl) | 2005-01-14 | 2014-03-31 | Chemocentryx Inc | Sulfonamidy heteroarylowe i CCR2 |
US7301022B2 (en) | 2005-02-15 | 2007-11-27 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
ATE502924T1 (de) | 2005-06-27 | 2011-04-15 | Bristol Myers Squibb Co | Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden |
WO2007002635A2 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
KR100975448B1 (ko) | 2005-09-23 | 2010-08-11 | 화이자 프로덕츠 인크. | 시토크롬 p450 3a4 (cyp3a4) 억제제로서의피리딘아미노술포닐 치환된 벤즈아미드 |
JP2009510144A (ja) | 2005-10-06 | 2009-03-12 | サノフィ−アベンティス | 4−オキシ−n−[1,3,4]−チアジアゾール−2−イル−ベンゼンスルホンアミド類、それらの製造方法及びそれらの医薬品としての使用 |
US7842819B2 (en) | 2005-10-21 | 2010-11-30 | Vertex Pharmaceuticals Incorporated | Derivatives for modulation of ion channels |
AR058296A1 (es) | 2005-12-09 | 2008-01-30 | Kalypsys Inc | Inhibidores de histona desacetilasa y composicion farmaceutica |
RU2441869C2 (ru) | 2005-12-21 | 2012-02-10 | Эбботт Лэборетриз | Противовирусные соединения |
JP5089185B2 (ja) | 2006-02-02 | 2012-12-05 | 大塚製薬株式会社 | コラーゲン産生抑制剤。 |
ES2452031T3 (es) | 2006-02-03 | 2014-03-31 | Eli Lilly & Company | Compuestos y procedimientos para modular receptores FX |
MX2008013114A (es) | 2006-04-14 | 2008-10-21 | Abbott Gmbh & Co Kg | Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3. |
GB0608386D0 (en) | 2006-04-27 | 2006-06-07 | Senexis Ltd | Compounds |
CA2656067C (en) | 2006-06-23 | 2014-08-12 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
EP2089365A1 (en) | 2006-10-05 | 2009-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derived metalloprotease inhibitors |
US20080255155A1 (en) | 2006-10-18 | 2008-10-16 | Stephane Raeppel | Kinase inhibitors and uses thereof |
ES2357340T3 (es) | 2006-10-18 | 2011-04-25 | Pfizer Products Inc. | Compuestos de biaril éter urea. |
WO2008050200A1 (en) | 2006-10-24 | 2008-05-02 | Pfizer Products Inc. | Oxadiazole compounds as calcium channel antagonists |
WO2008057280A1 (en) | 2006-10-27 | 2008-05-15 | Amgen Inc. | Multi-cyclic compounds and methods of use |
CA2695613A1 (en) | 2006-12-19 | 2008-06-26 | Pharmos Corporation | Sulfonamide derivatives with therapeutic indications |
AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
JP2008214222A (ja) | 2007-03-01 | 2008-09-18 | Tokyo Medical & Dental Univ | フェノール誘導体及びその医薬用途 |
CL2008000835A1 (es) | 2007-03-23 | 2008-10-03 | Icagen Inc Pfizer Ltd | Compuestos derivados de sulfonamidas, inhibidores de los canales de calcio; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor, sindrome de intestino irritable, enfermedad de crohn, taquiarritm |
ES2323927B1 (es) | 2007-03-30 | 2010-05-14 | Laboratorios Salvat, S.A. | Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga. |
US7960567B2 (en) | 2007-05-02 | 2011-06-14 | Amgen Inc. | Compounds and methods useful for treating asthma and allergic inflammation |
WO2008135826A2 (en) | 2007-05-03 | 2008-11-13 | Pfizer Limited | 2 -pyridine carboxamide derivatives as sodium channel modulators |
US7592342B2 (en) | 2007-05-10 | 2009-09-22 | Smithkline Beecham Corporation | Quinoxaline derivatives as PI3 kinase inhibitors |
US8124610B2 (en) | 2007-07-13 | 2012-02-28 | Icagen Inc. | Sodium channel inhibitors |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
SG183667A1 (en) | 2007-07-30 | 2012-09-27 | Encysive Pharmaceuticals Inc | Modulators of ccr9 receptor and methods of use thereof |
JP5544296B2 (ja) | 2007-11-16 | 2014-07-09 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝障害のためのカルボキサミド、スルホンアミド、およびアミン化合物 |
EP2291349A2 (en) | 2008-04-14 | 2011-03-09 | The Board of Regents of The University of Texas System | Small molecule inhibitors of the pleckstrin homology domain and methods for using same |
WO2009127822A2 (en) | 2008-04-16 | 2009-10-22 | Biolipox Ab | Bis-aryl compounds for use as medicaments |
PT2385938E (pt) * | 2009-01-12 | 2015-06-02 | Pfizer Ltd | Derivados de sulfonamida |
-
2010
- 2010-01-06 PT PT107027401T patent/PT2385938E/pt unknown
- 2010-01-06 MA MA34014A patent/MA32965B1/fr unknown
- 2010-01-06 GE GEAP201012293A patent/GEP20135992B/en unknown
- 2010-01-06 DK DK10702740T patent/DK2385938T3/en active
- 2010-01-06 HU HUE10702740A patent/HUE025013T2/hu unknown
- 2010-01-06 MX MX2011007424A patent/MX2011007424A/es active IP Right Grant
- 2010-01-06 UA UAA201108581A patent/UA105911C2/uk unknown
- 2010-01-06 ES ES10702740.1T patent/ES2536191T3/es active Active
- 2010-01-06 RS RS20150244A patent/RS53941B1/en unknown
- 2010-01-06 EA EA201170922A patent/EA020460B1/ru not_active IP Right Cessation
- 2010-01-06 CA CA2747419A patent/CA2747419C/en not_active Expired - Fee Related
- 2010-01-06 MY MYPI2011003158A patent/MY157017A/en unknown
- 2010-01-06 BR BRPI1006128A patent/BRPI1006128A2/pt not_active IP Right Cessation
- 2010-01-06 EP EP10702740.1A patent/EP2385938B1/en active Active
- 2010-01-06 KR KR1020117018770A patent/KR101345497B1/ko not_active IP Right Cessation
- 2010-01-06 NZ NZ593473A patent/NZ593473A/xx not_active IP Right Cessation
- 2010-01-06 CU CU2011000145A patent/CU24099B1/es active IP Right Grant
- 2010-01-06 CN CN201080011374.3A patent/CN102348697B/zh not_active Expired - Fee Related
- 2010-01-06 PE PE2011001300A patent/PE20120008A1/es not_active Application Discontinuation
- 2010-01-06 PE PE2014001348A patent/PE20142099A1/es not_active Application Discontinuation
- 2010-01-06 JP JP2011544954A patent/JP5053459B2/ja not_active Expired - Fee Related
- 2010-01-06 AP AP2011005788A patent/AP2811A/xx active
- 2010-01-06 PL PL10702740T patent/PL2385938T3/pl unknown
- 2010-01-06 AU AU2010204118A patent/AU2010204118B2/en not_active Ceased
- 2010-01-06 WO PCT/IB2010/050033 patent/WO2010079443A1/en active Application Filing
- 2010-01-07 TW TW099100267A patent/TWI419897B/zh not_active IP Right Cessation
- 2010-01-07 TW TW102136757A patent/TWI494317B/zh not_active IP Right Cessation
- 2010-01-11 UY UY0001032379A patent/UY32379A/es not_active Application Discontinuation
- 2010-01-11 AR ARP100100053A patent/AR075005A1/es unknown
- 2010-01-12 US US12/685,913 patent/US8153814B2/en not_active Expired - Fee Related
- 2010-01-12 HN HN2010000084A patent/HN2010000084A/es unknown
-
2011
- 2011-06-13 IL IL213517A patent/IL213517A/en not_active IP Right Cessation
- 2011-06-21 TN TN2011000316A patent/TN2011000316A1/fr unknown
- 2011-06-28 CR CR20110370A patent/CR20110370A/es unknown
- 2011-07-06 CL CL2011001658A patent/CL2011001658A1/es unknown
- 2011-07-08 SV SV2011003970A patent/SV2011003970A/es unknown
- 2011-07-08 DO DO2011000218A patent/DOP2011000218A/es unknown
- 2011-07-11 NI NI201100137A patent/NI201100137A/es unknown
- 2011-07-11 GT GT201100195A patent/GT201100195A/es unknown
- 2011-07-12 EC EC2011011198A patent/ECSP11011198A/es unknown
- 2011-07-22 CO CO11092086A patent/CO6400220A2/es active IP Right Grant
- 2011-07-27 ZA ZA2011/05530A patent/ZA201105530B/en unknown
-
2012
- 2012-02-20 US US13/400,356 patent/US8541588B2/en not_active Expired - Fee Related
- 2012-02-28 HK HK12102006.4A patent/HK1161253A1/xx not_active IP Right Cessation
-
2013
- 2013-08-16 US US13/968,561 patent/US8907101B2/en not_active Expired - Fee Related
-
2015
- 2015-03-30 HR HRP20150355TT patent/HRP20150355T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20142099A1 (es) | Derivados de sulfonamida | |
PE20091573A1 (es) | Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa | |
PE20091952A1 (es) | Compuestos de tiazole y oxazole de sulfonamida de benzeno | |
PE20090641A1 (es) | Amidas heterociclicas | |
PE20060079A1 (es) | DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5 | |
PE20090601A1 (es) | Derivados de piridin-il-oxi-piridinas como inhibidores de alk5 | |
PE20131377A1 (es) | Triazina-oxadiazoles | |
PE20110843A1 (es) | Derivados de 5-(1h-imidazol-5-il)-2-fenilpirimidina, como inhibidores de prostaglandina d sintasa hematopoyetica | |
PE20141375A1 (es) | Activadores de glucoquinasa | |
PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
PE20120693A1 (es) | Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2) | |
PE20081836A1 (es) | Derivados de piperidina como inhibidores de la sintasa de acido graso | |
PE20091925A1 (es) | Derivados de indazol sustituidos con fenilo o benzodioxinilo | |
PE20091026A1 (es) | Piperidinas heteroaril-sustituidas | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
PE20131153A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
PE20120101A1 (es) | Pirazoles fungicidas | |
PE20091842A1 (es) | Pirrolidinonas como activadores de glucoquinasa | |
PE20051173A1 (es) | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 | |
PE20120403A1 (es) | Aril-piridinas como inhibidoras de sintasa de aldosterona | |
PE20110574A1 (es) | Derivados de fenilamida y de piridilamida como agonistas de gpbar1 | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
PE20121047A1 (es) | Derivados de tiazolilpiperidina como fungicidas | |
PE20060937A1 (es) | Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2) | |
PE20141307A1 (es) | Aril dihidropiridinona y piperidinona como inhibidores de monoacilglicerol aciltransferasa (mgat2) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |